Juan Gonzalez-Moreno

Juan Gonzalez-Moreno

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 February 2018 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
MRManuel Raya-Cruz
Manuel Raya-Cruz
ILInés Losada
Inés Losada
ACAna Paula Cacheda
Ana Paula Cacheda
COCristina Oliver
Cristina Oliver
BCBartomeu Colom
Bartomeu Colom

20 December 2023 in Cardiology and Therapy
Verified
Journal Article
Open access
PDF file
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
ADAngela Dispenzieri
Angela Dispenzieri
MGMartha Grogan
Martha Grogan
TCTeresa Coelho
Teresa Coelho
ITIvailo Tournev
Ivailo Tournev
LALeslie Amass
Leslie Amass
Introduction Transthyretin amyloidosis (ATTR amyloidosis) is primarily associated with a cardiac or neurologic phenotype, but a mixed phenotype is increasingly described. Methods This study describes the mixed phenotype cohort in the Transthyretin Amyloidosis Outcomes Survey (THAOS). THAOS is an ongoing, longitudinal, observational survey of patients with ATTR amyloidosis, including both hereditary (ATTRv) and wild-type disease, and asymptomatic carriers of pathogenic transthyretin variants. Baseline characteristics of patients with a mixed phenotype (at enrollment or reclassified during follow-up) are described (data cutoff: January 4, 2022). Results Approximately one-third of symptomatic patients (n = 1185/3542; 33.5%) were classified at enrollment or follow-up as mixed phenotype (median age, 66.5 years). Of those, 344 (29.0%) were reclassified to mixed phenotype within a median 1–2 years of follow-up. Most patients with mixed phenotype had ATTRv amyloidosis (75.7%). The most frequent genotypes were V30M (38.9%) and wild type (24.3%). Conclusions These THAOS data represent the largest analysis of a real-world mixed phenotype ATTR amyloidosis population to date and suggest that a mixed phenotype may be more prevalent than previously thought. Patients may also migrate from a primarily neurologic or cardiologic presentation to a mixed phenotype over time. These data reinforce the need for multidisciplinary evaluation at initial assessment and follow-up of all patients with ATTR amyloidosis. Trial Registration ClinicalTrials.gov: NCT00628745.

30 July 2021 in Neurology and Therapy
Verified
Journal Article
Open access
PDF file
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
ILInés Losada-López
Inés Losada-López
ECEugenia Cisneros-Barroso
Eugenia Cisneros-Barroso
PGPablo Garcia-Pavia
Pablo Garcia-Pavia
JGJosé González-Costello
José González-Costello
LALeslie Amass
Leslie Amass
Introduction Transthyretin amyloidosis (ATTR amyloidosis) is a clinically heterogeneous disease caused by mutations in the transthyretin (TTR) gene or aggregation of wild-type transthyretin (ATTRwt). In Spain, there are two large endemic foci of ATTR amyloidosis caused by the Val30Met variant, with additional cases across the country; however, these data may be incomplete, as there is no centralized patient registry. The Transthyretin Amyloidosis Outcomes Survey (THAOS) is an ongoing, global, longitudinal, observational survey of patients with ATTR amyloidosis, including both inherited and wild-type disease, and asymptomatic patients with TTR mutations. This analysis aimed to gain a deeper understanding of the clinical profile of patients with ATTR amyloidosis in Spain. Methods This was a descriptive analysis of the demographic and clinical characteristics of symptomatic patients enrolled at six sites geographically dispersed throughout Spain (data cutoff: January 6, 2020). Patient data at enrollment, including genotype, demographics, and clinical presentation for symptomatic patients, were recorded. Patients were grouped by predominant phenotype based on clinical measures at enrollment: predominantly cardiac, predominantly neurologic, or mixed (cardiac and neurologic). Results There were 379 patients (58.0% male; 63.3% symptomatic) enrolled in the six THAOS sites in Spain. Predominant genotypes were the Val30Met mutation (69.1%) or ATTRwt (15.6%). Predominant phenotype distribution was neurologic (50.4%), mixed (35.8%), and cardiac (13.8%) for all symptomatic patients (n = 240); neurologic (67.8%), mixed (21.2%), and cardiac (11.0%) for symptomatic Val30Met (n = 146); and mixed (64.9%), cardiac (22.8%), and neurologic (12.3%) for symptomatic ATTRwt (n = 57). Symptomatic patients reported a range of ATTR amyloidosis signs and symptoms at enrollment, with autonomic neuropathy and sensory neuropathy common in all phenotypes. Conclusions These results from THAOS highlight the phenotypic heterogeneity associated with ATTR amyloidosis in Spain and the importance of comprehensive neurologic and cardiac evaluations in all patients with ATTR amyloidosis. Trial registration ClinicalTrials.gov: NCT00628745.

8 September 2014 in Lupus
Verified
Journal Article
Closed access
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
MRM Ruíz-Ruigomez
M Ruíz-Ruigomez
JRJ L Callejas Rubio
J L Callejas Rubio
RFR Ríos Fernández
R Ríos Fernández
NCN Ortego Centeno
N Ortego Centeno
Pyoderma gangrenosum (PG) is an uncommon, distinctive cutaneous ulceration which is usually idiopathic, but may be associated with many systemic disorders. The etiopathogenesis of PG is still not well understood. PG is part of the spectrum of the neutrophilic dermatoses and it has been proposed as a prototype of cutaneous autoinflammatory disease. PG usually has a good outcome under immunosuppressive treatment. Although PG has been associated with several systemic diseases, it has rarely been reported in association with systemic lupus erythematosus (SLE). In this article we report five cases of SLE-related PG and review the literature. Our findings support the possible relationship between active SLE and PG, although the mechanism remains unclear. Clinical manifestations, used treatments and outcomes of SLE-related PG do not differ from the described for the general population.

19 October 2017 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
MGMercedes García-Gasalla
Mercedes García-Gasalla
ILInés Losada
Inés Losada
CLCarmen Cifuentes Luna
Carmen Cifuentes Luna
IVIsabel Mir Viladrich
Isabel Mir Viladrich
ACAntoni Payeras Cifre
Antoni Payeras Cifre

20 May 2016 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JGJuan Gonzalez-Moreno
Juan Gonzalez-Moreno
ILInés Losada
Inés Losada
CGCristina Gállego-Lezaun
Cristina Gállego-Lezaun
MGMercedes García-Gasalla
Mercedes García-Gasalla
CBCristina Gómez Bellvert
Cristina Gómez Bellvert
NCNorberto Ortego Centeno
Norberto Ortego Centeno